TLOG (TetraLogic Pharmaceuticals) EV-to-EBITDA: 0.00 (As of Jul. 08, 2026)

What is TetraLogic Pharmaceuticals EV-to-EBITDA?

TetraLogic Pharmaceuticals TLOG EV-to-EBITDA is 0.00 as of Jul. 08, 2026.

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, TetraLogic Pharmaceuticals's enterprise value is $0.00 Mil. TetraLogic Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Sep. 2016 was $-36.09 Mil. Therefore, TetraLogic Pharmaceuticals's EV-to-EBITDA for today is 0.00.

The historical rank and industry rank for TetraLogic Pharmaceuticals's EV-to-EBITDA or its related term are showing as below:

TLOG's EV-to-EBITDA is not ranked ^*
in the Biotechnology industry.
Industry Median: 13.38
* Ranked among companies with meaningful EV-to-EBITDA only.

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2026-07-08), TetraLogic Pharmaceuticals's stock price is $4.0E-5. TetraLogic Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2016 was $-1.650. Therefore, TetraLogic Pharmaceuticals's PE Ratio (TTM) for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).

TetraLogic Pharmaceuticals (OTCPK:TLOG) EV-to-EBITDA Explanation

TetraLogic Pharmaceuticals's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)	=	Share Price (Today)	/	Earnings per Share (Diluted) (TTM)
	=	4.0E-5	/	-1.650
	=	At Loss

TetraLogic Pharmaceuticals's share price for today is $4.0E-5.
TetraLogic Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2016 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.650.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).

Please read Which price ratio outperforms the enterprise multiple?

TetraLogic Pharmaceuticals EV-to-EBITDA Related Terms

TetraLogic Pharmaceuticals EV-to-EBITDA Historical Data

* Premium members only.

The historical data trend for TetraLogic Pharmaceuticals's EV-to-EBITDA can be seen below:

TetraLogic Pharmaceuticals EV-to-EBITDA Chart

TetraLogic Pharmaceuticals Annual Data

Trend

Dec11

Dec12

Dec13

Dec14

Dec15

EV-to-EBITDA

0.00

-9.14

-2.48

-1.18

TetraLogic Pharmaceuticals Quarterly Data
	Dec11	Sep12	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16
EV-to-EBITDA	Get a 7-Day Free Trial													-1.10	-1.18	-0.46	-0.80	-0.80

TLOG vs ARGSQ, GTHR, SOAN: EV-to-EBITDA Comparison

For the Biotechnology subindustry, TetraLogic Pharmaceuticals's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

TetraLogic Pharmaceuticals EV-to-EBITDA vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, TetraLogic Pharmaceuticals's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where TetraLogic Pharmaceuticals's EV-to-EBITDA falls into.

Save Embed

TetraLogic Pharmaceuticals EV-to-EBITDA Calculation

TetraLogic Pharmaceuticals's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA	=	Enterprise Value (Today)	/	EBITDA (TTM)
	=	0.000	/	-36.086
	=	0.00

TetraLogic Pharmaceuticals's current Enterprise Value is $0.00 Mil.
TetraLogic Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Sep. 2016 adds up the quarterly data reported by the company within the most recent 12 months, which was $-36.09 Mil.

Frequently Asked Questions Learn more about EV-to-EBITDA →

What does a EV-to-EBITDA of 0.00 mean?

TetraLogic Pharmaceuticals (TLOG) has a EV-to-EBITDA of 0.00 as of Jul. 08, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on TetraLogic Pharmaceuticals.

Is TetraLogic Pharmaceuticals' EV-to-EBITDA too high?

TetraLogic Pharmaceuticals' current EV-to-EBITDA is 0.00.

How does TetraLogic Pharmaceuticals' EV-to-EBITDA compare to ARGSQ and GTHR?

TetraLogic Pharmaceuticals' EV-to-EBITDA of 0.00 can be compared against companies in the Biotechnology industry. The industry median EV-to-EBITDA is 13.38. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good EV-to-EBITDA for a Biotechnology company?

The median EV-to-EBITDA among Biotechnology companies is 13.38, based on 391 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high EV-to-EBITDA mean?

A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on TetraLogic Pharmaceuticals. For the Biotechnology industry, the median EV-to-EBITDA is 13.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. TetraLogic Pharmaceuticals's current EV-to-EBITDA is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is TetraLogic Pharmaceuticals stock overvalued right now?

TetraLogic Pharmaceuticals (TLOG) has a current EV-to-EBITDA of 0.00. The current EV-to-EBITDA is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is EV-to-EBITDA calculated?

EV-to-EBITDA is calculated from a company's financial statements. For TetraLogic Pharmaceuticals (TLOG), the current EV-to-EBITDA is 0.00 as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

TetraLogic Pharmaceuticals Business Description

Industry Healthcare Biotechnology

Comparable Companies ARGSQ GTHR SOAN CTBO BOM:524604 GWSN WAR:PFM TSXV:PBS IMUC MBVXQ NTRR STLT XSAT:EURI B HSTC BOM:506365 BOM:532041 ATMS BOM:524796 LSE:ANIC TSXV:COT

Address 343 Phoenixville Pike, Malvern, PA, USA, 19355

Website http://www.tetralogicpharma.com

TetraLogic Pharmaceuticals Corp is a biopharmaceutical company. The company is engaged in developing novel small molecule therapeutics in oncology.